EnhanceTM Platform

Cell expansion
& Rejuvenation

Proprietary platform designed to help cell & gene therapy companies deliver greater doses of functional cells by expanding HSCs from any source and counteracting the effects of cell manipulation induced stress

  1. Science 2014; Lancet Hematol 2020; Cell Stem Cell 2021; Mol Ther Methods Clin Dev 2018 and many others; Collaboration in the field of PSCs with Astellas; Collaborations with several cell & gene therapy companies.
  2. Stem cells cultured with UM171 maintain greater factors associated with “stemness” or quiescence (adapted from Nakamura-Ishizu A., Dev Cell. 2020).

EnhanceTM Platform
for cell and gene therapies

UM171

UM171 is the Standard for Ex Vivo HSC Expansion in Cell & Gene Therapy.

UM171 discovery and optimization published in:

Full results of initial clinical trial published in:

UM171 mechanism of action published in:

Comparative real world study published in:

  • Best molecule and first-in class mechanism of action for HSC expansion1
  • UM171-expanded cells maintain better stemness2
  • Clinically validated in over 100 patients3
  • GMP grade molecule supported by Drug Master File (DMF)
  • Frequently cited in major scientific publications
  • Patent protected worldwide
  • Used under license by institutions and bio-pharmas
  1. Science 2014; Lancet Hematol 2020; Cell Stem Cell 2021; Mol Ther Methods Clin Dev 2018 and many others; Collaboration in the field of PSCs with Astellas; Collaborations with several cell & gene therapy companies.
  2. Stem cells cultured with UM171 maintain greater factors associated with “stemness” or quiescence (adapted from Nakamura-Ishizu A., Dev Cell. 2020).
  3. 100+ patients treated with UM171-expanded cells; initial clinical trials results published in Lancet Heamatology (2020); CIBMTR matched-controlled study published in Blood Advances (2023).